FDA Panel Rejects Combo Drug for PTSD
An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti,…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
FDA Approves First Treatment for MAS in Still Disease
The FDA has approved the interferon gamma-blocking antibody emapalumab-lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS)…
Injectable HIV Prevention Drug Gets FDA Nod
Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the…